CIMG Reports Significant Revenue Growth in Q4 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Source: Newsfilter
- Significant Revenue Growth: CIMG achieved revenue of $15,768,796 in Q4 2025, a substantial increase from $22,853 in the same period of 2024, reflecting strong early-stage commercialization of its medicine-food homology products and computing power solutions, indicating the potential of new business lines.
- Digital Asset Expansion: As of December 31, 2025, the company held 730 Bitcoins with a carrying value of $63,978,821, demonstrating the effectiveness of its investment strategy in digital assets and enhancing its financial stability.
- Accelerated Global Layout: During Q4 2025, CIMG established wholly-owned subsidiaries in Shenzhen and Foshan, China, and acquired Braincon Limited and its subsidiary, significantly improving its production, sales, and R&D capabilities in the Asian market, thereby strengthening localized operational advantages.
- Ongoing Strategic Transformation: CIMG will continue to focus on a dual-track strategy for health consumer goods and computing power technology products, planning to optimize product pricing and cost control while increasing R&D investment in computing power products to enhance gross margins and expand its enterprise customer base.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
